Ivan Rickard
National Market Access Manager Uk Ire Biosimilars @Biogen
Signup · Get unlimited contacts
WORK HISTORY
National Market Access Manager Uk Ire Biosimilars @Biogen
Maidenhead, GB
EDUCATION
University of Derby
BSc Hons, Geography
SKILLS
ABOUT IVAN RICKARD
High performing manager within the health care industry with a unique track record in planning and executing blockbuster launches and life cycle management optimisation across multiple therapy areas with Biosimilars.Part of the founding leadership team that built the Biogen Biosimilars Business Unit:$100m sales in the first launch year (2016) Europe. and with continued strong grow market leader within the UK marketplaceMarket Access working with the NHS to accommodate changing health care environment; defining, setting and managing national pricing, reimbursement and tendering strategies Achievements:• Chairmans award for 2020, outstanding performance and results in Ireland with Biosimllars.• CEO Element Award Winner for 2021, Expanding access to biologic treatment (new NICE guidance for moderate RA patients)• ISPOR (The Professional Society for Health Economics and Outcomes Research) 2021 the digital simulation modelling to deliver an effective IV IFX service has been identified as a top 5% finalist from the 1,200 submissions across the conference “Understanding optimal resource allocations to deliver a sustainable IV infliximab infusion service through digital innovation.”• EVP (European Vice President) 2022 ‘Staying Connected’ Award winner, the award demonstrates how we highly connected to key customers (NHS in the UK) throughout the COVID crisis to understand needs, to address the Green/Environmental aspects in public procurement.• EVP (European Vice President) 2022‘Award Winners for Staying Connected from Germany and UK, always striving every day to make a difference by driving impact, staying connected, celebrating uniqueness and being resilient.• 1# winner “Best Use of Innovation” simulation modelling 2023, The BOBI award (Best of Business Intelligence), which recognises excellence across the healthcare business intelligence spectrum.• Published Value in Health, June 2023. Utilisation of the Cost-Saving Impact of Biosimilar Switching in Ophthalmological Diseases in the NHS: A Case-Study for a Ranibizumab Biosimilar
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.